Kazia Therapeutics Appoints Dr. Sudha Rao as Chief Scientific Officer, Bolstering Oncology R&D

summarizeSummary

Kazia Therapeutics appointed Dr. Sudha Rao, a key scientific originator of its core assets and pioneer in new platforms, as Chief Scientific Officer, enhancing its oncology R&D strategy.

check_boxKey Events

• Chief Scientific Officer Appointed

  Dr. Sudha Rao has been formally appointed as Chief Scientific Officer (CSO), effective April 13, 2026, to lead the company's research and development activities.

• Highly Qualified Scientific Leader

  Dr. Rao is recognized as the scientific originator of the epigenetic framework for paxalisib and a pioneer in next-generation platforms like PD-L1 protein degradation and SETDB1-targeted chromatin modulation, with 39 international patents.

• Strategic Alignment with Pipeline

  Her expertise directly supports Kazia's key programs, including paxalisib, NDL2, and MSETC, and will drive the company's biomarker strategy and external collaborations.

• Compensation Package Includes Significant Equity

  Dr. Rao will receive an annual base salary of AUD$325,000 and a grant of 250,000 American Depositary Share (ADS) options, vesting over two years, subject to Board approval.

auto_awesomeAnalysis

Kazia Therapeutics has formally appointed Dr. Sudha Rao as its Chief Scientific Officer, a strategic move that significantly strengthens the company's research and development capabilities. Dr. Rao is a highly accomplished translational scientist and the scientific originator of the epigenetic framework underlying paxalisib, a key asset, and a pioneer in next-generation therapeutic platforms, including the recently licensed SETDB1-targeted chromatin modulation program. Her expertise is directly aligned with Kazia's integrated oncology platform strategy, which includes paxalisib, NDL2 (PD-L1 degrader), and MSETC (SETDB1 program). The appointment, which includes an annual base salary of AUD$325,000 and a grant of 250,000 ADS options vesting over two years, provides substantial incentive for a leader critical to advancing the company's pipeline and biomarker strategy. This formal SEC filing provides detailed terms following earlier news reports, confirming a pivotal hire for the company's scientific future.